These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 31672647)
41. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients. Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454 [TBL] [Abstract][Full Text] [Related]
42. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Silva-Santos RM; Costa-Pinheiro P; Luis A; Antunes L; Lobo F; Oliveira J; Henrique R; Jerónimo C Br J Cancer; 2013 Nov; 109(10):2646-53. PubMed ID: 24129247 [TBL] [Abstract][Full Text] [Related]
43. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498 [TBL] [Abstract][Full Text] [Related]
45. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma. Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793 [TBL] [Abstract][Full Text] [Related]
46. miR-210 is a prognostic marker in clear cell renal cell carcinoma. Samaan S; Khella HW; Girgis A; Scorilas A; Lianidou E; Gabril M; Krylov SN; Jewett M; Bjarnason GA; El-said H; Yousef GM J Mol Diagn; 2015 Mar; 17(2):136-44. PubMed ID: 25555365 [TBL] [Abstract][Full Text] [Related]
47. MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs. He H; Wang L; Zhou W; Zhang Z; Wang L; Xu S; Wang D; Dong J; Tang C; Tang H; Yi X; Ge J PLoS One; 2015; 10(5):e0125672. PubMed ID: 25938468 [TBL] [Abstract][Full Text] [Related]
48. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Petrozza V; Pastore AL; Palleschi G; Tito C; Porta N; Ricci S; Marigliano C; Costantini M; Simone G; Di Carlo A; Gallucci M; Carbone A; Fazi F Oncotarget; 2017 Sep; 8(41):69551-69558. PubMed ID: 29050224 [TBL] [Abstract][Full Text] [Related]
49. Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data. Guan L; Tan J; Li H; Jin X Gene; 2018 Mar; 647():205-212. PubMed ID: 29253611 [TBL] [Abstract][Full Text] [Related]
50. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025 [TBL] [Abstract][Full Text] [Related]
52. Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma. Okato A; Arai T; Yamada Y; Sugawara S; Koshizuka K; Fujimura L; Kurozumi A; Kato M; Kojima S; Naya Y; Ichikawa T; Seki N Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902136 [TBL] [Abstract][Full Text] [Related]
54. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988 [TBL] [Abstract][Full Text] [Related]
55. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers. Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440 [TBL] [Abstract][Full Text] [Related]
56. Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma. Kaneko S; Matsumoto K; Minamida S; Hirayama T; Fujita T; Kodera Y; Iwamura M Asian Pac J Cancer Prev; 2016; 17(3):1399-404. PubMed ID: 27039779 [TBL] [Abstract][Full Text] [Related]
57. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Hauser S; Wulfken LM; Holdenrieder S; Moritz R; Ohlmann CH; Jung V; Becker F; Herrmann E; Walgenbach-Brünagel G; von Ruecker A; Müller SC; Ellinger J Cancer Epidemiol; 2012 Aug; 36(4):391-4. PubMed ID: 22542158 [TBL] [Abstract][Full Text] [Related]
58. Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma. Zhao Z; Lu J; Qu H; Wang Z; Liu Q; Yang X; Liu S; Ge J; Xu Y; Li N; Yuan Y Hum Pathol; 2018 Oct; 80():87-93. PubMed ID: 29935195 [TBL] [Abstract][Full Text] [Related]
59. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464 [TBL] [Abstract][Full Text] [Related]
60. MicroRNAs as Urinary Biomarker for Oncocytoma. von Brandenstein M; Schlosser M; Herden J; Heidenreich A; Störkel S; Fries JWU Dis Markers; 2018; 2018():6979073. PubMed ID: 30116406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]